A prognostic model for metastatic renal-cell carcinoma
Menée sur 1 028 patients atteints d'un carcinome métastatique à cellules rénales, cette étude internationale évalue, par rapport à quatre outils existants, les performances d'un outil appelé "International Metastatic Renal-Cell Carcinoma Database Consortium" pour estimer la survie globale des patients
The fact that patients with metastatic renal-cell carcinoma (RCC) have heterogeneous clinical outcomes has long been recognised. In an effort to help patient counselling and stratification for clinical trials, several prognostic models based on pretreatment variables have been developed in the past few decades. Of these models, the Memorial Sloan-Kettering Cancer Center (MSKCC) model has been widely accepted and was used in the design of many of the clinical trials that have led to the current treatment standards...
The Lancet Oncology , commentaire en libre accès, 2012